Luteinizing hormone-releasing hormone agonist triptorelin in combination with cytotoxic chemotherapy in patients with advanced ovarian carcinoma. A prospective double blind randomized trial. Decapeptyl Ovarian Cancer Study Group (Q71611166)

From Wikidata

Jump to navigation Jump to search

scientific article published on 01 October 1996

Language	Label	Description	Also known as
English	Luteinizing hormone-releasing hormone agonist triptorelin in combination with cytotoxic chemotherapy in patients with advanced ovarian carcinoma. A prospective double blind randomized trial. Decapeptyl Ovarian Cancer Study Group	scientific article published on 01 October 1996

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8839551%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

Luteinizing hormone-releasing hormone agonist triptorelin in combination with cytotoxic chemotherapy in patients with advanced ovarian carcinoma. A prospective double blind randomized trial. Decapeptyl Ovarian Cancer Study Group (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8839551%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8839551%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

author name string

Emons G

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8839551%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

Ortmann O

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8839551%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

Teichert HM

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8839551%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

Fassl H

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8839551%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

Löhrs U

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8839551%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

Kullander S

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8839551%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

Kauppila A

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8839551%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

Ayalon D

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8839551%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

Oberheuser F

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8839551%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

language of work or name

0 references

publication date

1 October 1996

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8839551%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8839551%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

78

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8839551%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8839551%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

1452-1460

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8839551%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

Inhibition of human epithelial ovarian cancer cell growth in vitro by agonistic and antagonistic analogues of luteinizing hormone-releasing hormone

0 references

Epithelial ovarian carcinoma: principles of primary surgery

0 references

Leukemia following chemotherapy for ovarian cancer.

0 references

Tamoxifen in combination with cytotoxic chemotherapy in advanced epithelial ovarian cancer. A prospective randomized trial

0 references

Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer

0 references

Gonadotropin-releasing hormone receptor in gynecologic tumors. Frequent expression in adenocarcinoma histologic types

0 references

Endocrine Factors in Common Epithelial Ovarian Cancer*

0 references

Hormonal palliation of chemoresistant ovarian cancer: three consecutive phase II trials of the Mid-Atlantic Oncology Program

0 references

The use of luteinizing hormone releasing hormone agonists and antagonists in gynaecological cancers

0 references

A phase II trial of goserelin (Zoladex) in relapsed epithelial ovarian cancer

0 references

Introduction to sample size determination and power analysis for clinical trials

0 references

Second-look laparotomy in ovarian cancer

0 references

Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients

0 references

Some observations on the effect of a GnRH analog in ovarian cancer

0 references

Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75.

0 references

Myelodysplastic syndrome after cisplatin therapy

0 references

Advances in the chemotherapy of gynecologic cancer.

0 references

Analogues of luteinizing hormone-releasing hormone containing cytotoxic groups

0 references

Presence of gonadotropin-releasing hormone and its messenger ribonucleic acid in human ovarian epithelial carcinoma

0 references

Treatment of advanced refractory ovarian carcinoma with a gonadotropin-releasing hormone analogue.

0 references

Cyclophosphamide, cisplatin, and leuprolide acetate in patients with debulked stage III or IV ovarian carcinoma

0 references

Leuprolide acetate in the treatment of refractory or persistent epithelial ovarian cancer

0 references

Response to D-Trp-6-luteinising hormone releasing hormone (Decapeptyl) microcapsules in advanced ovarian cancer.

0 references

Secondary myelodysplasia and acute leukemia following carboplatin-containing combination chemotherapy for ovarian cancer

0 references

Pneumothorax after fine needle aspiration of the breast.

0 references

Lupron retards proliferation of ovarian epithelial tumor cells cultured in serum-free medium

0 references

Identifiers

10.1002/(SICI)1097-0142(19961001)78:7<1452::AID-CNCR12>3.0.CO;2-Z

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8839551%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q71611166&oldid=1758000324"